Blog
RSS FeedPosted by Michael Wonder on 27 Sep 2023
ICER appoints Daniel Ollendorf as Chief Scientific Officer and Director of HTA Methods and Engagement
27 September 2023 - Academic leader in HTA to rejoin ICER in November 2023. ...
Posted by Michael Wonder on 25 Sep 2023
ICER releases draft evidence report on treatment for pulmonary arterial hypertension
25 September 2023 - Registration now open for 5 October “Early Insights” webinar. ...
Posted by Michael Wonder on 25 Sep 2023
ICER finalises 2023 updates to value assessment framework
25 September 2023 - Updates to methods and public meeting procedures reflect experience with previous framework, benchmarking with other HTA groups, ...
Posted by Michael Wonder on 14 Sep 2023
ICER publishes evidence report on gene therapy for metachromatic leukodystrophy
14 September 2023 - Using weighted analyses across all patient subpopulations, atidarsagene autotemcel would achieve common thresholds for cost effectiveness if priced ...
Posted by Michael Wonder on 11 Sep 2023
An alternative measure of health for value assessment: the equal value life-year
10 September 2023 - The quality-adjusted life-year (QALY) is an international standard in cost-effectiveness analysis. A known concern arises from the ...
Posted by Michael Wonder on 21 Aug 2023
ICER publishes final evidence report on gene therapies for sickle cell disease
21 August 2023 - Current evidence suggests that lovo-cel and exa-cel would achieve common thresholds for cost-effectiveness if priced between $1.35 ...
Posted by Michael Wonder on 26 Jul 2023
ICER releases draft evidence report on treatment for metachromatic leukodystrophy
26 July 2023 - Registration now open for 3 August “Early Insights” webinar. ...
Posted by Michael Wonder on 25 Jul 2023
ICER to assess treatments for paroxysmal nocturnal haemoglobinuria
25 July 2023 - Report will be subject of CTAF meeting in February 2024; draft scoping document open to public ...
Posted by Michael Wonder on 13 Jul 2023
ICER publishes evidence report on gene therapies for sickle cell disease
13 July 2023 - In the short term, both lovo-cel and exa-cel can dramatically reduce the frequency of painful crises ...
Posted by Michael Wonder on 11 Jul 2023
ICER launches a patient council to amplify the patient voice in value assessment
11 July 2023 - Patient Council will advise ICER on engaging with patient groups while also identifying strategies to communicate ...
Posted by Michael Wonder on 05 Jul 2023
ICER to assess treatment for schizophrenia
5 July 2023 - Report will be subject of New England CEPAC meeting in February 2024; draft scoping document open ...
Posted by Michael Wonder on 28 Jun 2023
ICER announces leadership transition
28 June 2023 - Founder and President Steve Pearson to transition to advisor role at beginning of 2024; long-time EVP ...
Posted by Michael Wonder on 21 Jun 2023
ICER receives grant from The Commonwealth Fund for annual assessment of coverage policies that present barriers to fair access
21 June 2023 - ICER’s third annual “Barriers to Fair Access” report will be published in November 2023. ...
Posted by Michael Wonder on 08 Jun 2023
Congress’ misguided plan to ban QALYs
8 June 2023 - Paying for health care is a challenge for many Americans, but the House of Representatives is on ...
Posted by Michael Wonder on 05 Jun 2023
ICER proposes updates to value assessment framework methods and procedures
5 June 2023 - Proposed updates reflect experience with current framework, benchmarking with other health technology assessment groups, and external stakeholder ...